JPMorgan Chase & Co. Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price target lowered by investment analysts at JPMorgan Chase & Co. from $6.00 to $5.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 64.74% from the stock’s current price.

GDRX has been the subject of a number of other research reports. Mizuho cut their price objective on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. TD Cowen decreased their target price on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial lowered GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Finally, Weiss Ratings lowered GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.52.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded down $0.03 during trading hours on Tuesday, hitting $3.04. 418,180 shares of the company’s stock were exchanged, compared to its average volume of 2,508,738. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of 33.72, a PEG ratio of 1.62 and a beta of 1.20. The company’s 50-day moving average price is $4.00 and its 200-day moving average price is $4.27. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. GoodRx has a 1-year low of $2.95 and a 1-year high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. During the same quarter last year, the firm earned $0.08 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year. GoodRx has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.17% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. increased its holdings in GoodRx by 54.6% during the 1st quarter. Raymond James Financial Inc. now owns 830,950 shares of the company’s stock valued at $3,664,000 after purchasing an additional 293,420 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in GoodRx by 20,956.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company’s stock worth $64,000 after purchasing an additional 14,460 shares in the last quarter. Algert Global LLC bought a new stake in shares of GoodRx during the first quarter worth $1,224,000. XTX Topco Ltd acquired a new position in GoodRx during the 1st quarter worth about $315,000. Finally, EP Wealth Advisors LLC bought a new stake in GoodRx during the 1st quarter worth about $69,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.